Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins.
Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
Alba L MontoyaDepartment of Chemistry and Biochemistry, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, U.S.A.ORCID 0000-0002-1803-1564
Augusto M CarvalhoInstituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, BA, Brazil.
Brunele S de MendonçaInstituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, BA, Brazil.
Susana PortilloDepartment of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, U.S.A.ORCID 0000-0002-5210-0797
Janet J OlivasDepartment of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, U.S.A.
Nasim H KarimiDepartment of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, U.S.A.
Igor L EstevaoDepartment of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, U.S.A.ORCID 0000-0003-3946-8375
Uriel Ortega-RodriguezDepartment of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, U.S.A.ORCID 0000-0002-1700-357X
Edgar M CarvalhoInstituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, BA, Brazil.
Walderez O DutraInstituto Nacional de Ciência e Tecnologia de Doenças Tropicais, Salvador, BA, Brazil.ORCID 0000-0002-7586-9996
Rosa A MaldonaldoDepartment of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, U.S.A.
Katja MichaelDepartment of Chemistry and Biochemistry, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, U.S.A.ORCID 0000-0001-6754-3702
Camila I de OliveiraInstituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, BA, Brazil.ORCID 0000-0002-7868-5164
Igor C AlmeidaDepartment of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, U.S.A.ORCID 0000-0002-2443-8213
The University of Texas at El Paso · USFundação Oswaldo Cruz · BRInstituto Nacional de Ciência e Tecnologia de Doenças Tropicais · BRUniversidade Federal de Minas Gerais · BR
Funding
UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI Robert A. Kirken · 2019 to 2026
$35.1M
Phase II of BUILDing SCHOLARSUL1GM118970 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI ALEY, STEPHEN B, BOLAND, THOMAS · 2015 to 2023
$17.9M
RISE Scholars Program at UTEPR25GM069621 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2004 to 2021
$11.2M
Phase II of BUILDing SCHOLARS - Student Training CoreTL4GM118971 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI ALEY, STEPHEN B, BOLAND, THOMAS · 2015 to 2023
$9.9M
Phase II of BUILDing SCHOLARS - Research Enrichment CoreRL5GM118969 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI ALEY, STEPHEN B, BOLAND, THOMAS · 2015 to 2023
$7.4M
Inflammation in the Pathogenesis of Disseminated LeishmaniasisU01AI136032 · NIAID · FEDERAL UNIVERSITY OF BAHIA · PI CARVALHO, EDGAR M · 2017 to 2021
$1.6M
Differential diagnosis of cutaneous leishmaniasis by immunoassays with density-controlled presentation of glycan biomarkersR21AI137890 · NIAID · UNIVERSITY OF TEXAS EL PASO · PI MICHAEL, KATJA · 2018 to 2019
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins. · full record | OpenQuestion